Troponin T and N-Terminal Pro-B-type natriuretic peptide

A biomarker approach to predict heart failure risk-the atherosclerosis risk in communities study

Vijay Nambi, Xiaoxi Liu, Lloyd E. Chambless, James A de Lemos, Salim S. Virani, Sunil Agarwal, Eric Boerwinkle, Ron C. Hoogeveen, David Aguilar, Brad C. Astor, Pothur R. Srinivas, Anita Deswal, Thomas H. Mosley, Josef Coresh, Aaron R. Folsom, Gerardo Heiss, Christie M. Ballantyne

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value. Weevaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described. RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF. Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively). Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model. CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction. A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NTproBNP to clinical characteristics results in an excellent HF prediction model.

Original languageEnglish (US)
Pages (from-to)1802-1810
Number of pages9
JournalClinical Chemistry
Volume59
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Troponin T
Brain Natriuretic Peptide
Biomarkers
Atherosclerosis
Heart Failure
Area Under Curve
peptide A
Blood Pressure
ROC Curve
Blood pressure
Antihypertensive Agents
Coronary Disease
Medical problems
Body Mass Index
Cardiovascular Diseases
Heart Rate
Smoking
Assays

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Troponin T and N-Terminal Pro-B-type natriuretic peptide : A biomarker approach to predict heart failure risk-the atherosclerosis risk in communities study. / Nambi, Vijay; Liu, Xiaoxi; Chambless, Lloyd E.; de Lemos, James A; Virani, Salim S.; Agarwal, Sunil; Boerwinkle, Eric; Hoogeveen, Ron C.; Aguilar, David; Astor, Brad C.; Srinivas, Pothur R.; Deswal, Anita; Mosley, Thomas H.; Coresh, Josef; Folsom, Aaron R.; Heiss, Gerardo; Ballantyne, Christie M.

In: Clinical Chemistry, Vol. 59, No. 12, 12.2013, p. 1802-1810.

Research output: Contribution to journalArticle

Nambi, V, Liu, X, Chambless, LE, de Lemos, JA, Virani, SS, Agarwal, S, Boerwinkle, E, Hoogeveen, RC, Aguilar, D, Astor, BC, Srinivas, PR, Deswal, A, Mosley, TH, Coresh, J, Folsom, AR, Heiss, G & Ballantyne, CM 2013, 'Troponin T and N-Terminal Pro-B-type natriuretic peptide: A biomarker approach to predict heart failure risk-the atherosclerosis risk in communities study', Clinical Chemistry, vol. 59, no. 12, pp. 1802-1810. https://doi.org/10.1373/clinchem.2013.203638
Nambi, Vijay ; Liu, Xiaoxi ; Chambless, Lloyd E. ; de Lemos, James A ; Virani, Salim S. ; Agarwal, Sunil ; Boerwinkle, Eric ; Hoogeveen, Ron C. ; Aguilar, David ; Astor, Brad C. ; Srinivas, Pothur R. ; Deswal, Anita ; Mosley, Thomas H. ; Coresh, Josef ; Folsom, Aaron R. ; Heiss, Gerardo ; Ballantyne, Christie M. / Troponin T and N-Terminal Pro-B-type natriuretic peptide : A biomarker approach to predict heart failure risk-the atherosclerosis risk in communities study. In: Clinical Chemistry. 2013 ; Vol. 59, No. 12. pp. 1802-1810.
@article{8b8c8acaf6764a92b26b44817d780e78,
title = "Troponin T and N-Terminal Pro-B-type natriuretic peptide: A biomarker approach to predict heart failure risk-the atherosclerosis risk in communities study",
abstract = "BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value. Weevaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ({"}laboratory report{"} model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described. RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF. Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7{\%} and 54.7{\%} in women and men, respectively). Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model. CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction. A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NTproBNP to clinical characteristics results in an excellent HF prediction model.",
author = "Vijay Nambi and Xiaoxi Liu and Chambless, {Lloyd E.} and {de Lemos}, {James A} and Virani, {Salim S.} and Sunil Agarwal and Eric Boerwinkle and Hoogeveen, {Ron C.} and David Aguilar and Astor, {Brad C.} and Srinivas, {Pothur R.} and Anita Deswal and Mosley, {Thomas H.} and Josef Coresh and Folsom, {Aaron R.} and Gerardo Heiss and Ballantyne, {Christie M.}",
year = "2013",
month = "12",
doi = "10.1373/clinchem.2013.203638",
language = "English (US)",
volume = "59",
pages = "1802--1810",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "12",

}

TY - JOUR

T1 - Troponin T and N-Terminal Pro-B-type natriuretic peptide

T2 - A biomarker approach to predict heart failure risk-the atherosclerosis risk in communities study

AU - Nambi, Vijay

AU - Liu, Xiaoxi

AU - Chambless, Lloyd E.

AU - de Lemos, James A

AU - Virani, Salim S.

AU - Agarwal, Sunil

AU - Boerwinkle, Eric

AU - Hoogeveen, Ron C.

AU - Aguilar, David

AU - Astor, Brad C.

AU - Srinivas, Pothur R.

AU - Deswal, Anita

AU - Mosley, Thomas H.

AU - Coresh, Josef

AU - Folsom, Aaron R.

AU - Heiss, Gerardo

AU - Ballantyne, Christie M.

PY - 2013/12

Y1 - 2013/12

N2 - BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value. Weevaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described. RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF. Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively). Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model. CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction. A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NTproBNP to clinical characteristics results in an excellent HF prediction model.

AB - BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value. Weevaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described. RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF. Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively). Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model. CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction. A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NTproBNP to clinical characteristics results in an excellent HF prediction model.

UR - http://www.scopus.com/inward/record.url?scp=84889041779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889041779&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2013.203638

DO - 10.1373/clinchem.2013.203638

M3 - Article

VL - 59

SP - 1802

EP - 1810

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 12

ER -